周彩存 主任医师，教授
硕士招生类型：学术型；专业型
硕士招生专业：肿瘤学
博士招生类型：学术型；专业型
博士招生专业：肿瘤学
所在院系：附属肺科医院
联系方式：caicunzhoudr@163.com
课题组链接：
研究方向
主要任职
科研业绩

肺癌早期诊断；肺癌的靶向、免疫以及综合治疗。
Early diagnosis of lung cancer；Targeted therapy, immunotherapy andcomprehensive treatment of lung cancer.




同济大学附属上海市肺科医院肿瘤科行政主任，同济大学医学院肿瘤研究所所长，同济大学肿瘤学系主任，国际肺癌研究协会理事会核心成员、CSCO非小细胞肺癌专委会主任委员、中国医促会胸部肿瘤分会主任委员、上海市抗癌协会肺癌肺癌靶向和免疫治疗专委会主任委员、中国抗癌协会肺癌专业委员会常务委员、中国医师学会肿瘤医师分会常务委员、国际肺癌联盟（IASLC）控烟委员会委员、CSCO执行委员以及上海市肺科学会和肿瘤学会委员。
Director of Medical Oncology, Shanghai Pulmonary Hospital,Tongji university. Director of Tongji University Medical School Cancer Institute.Director of Oncology Major in Tongji University. Board of Directors of InternationalAssociation for the Study of Lung Cancer. Director of CSCO NSCLC Professional Committee.Standing Committee member of Chinese Society of Lung Cancer. ExecutiveCommittee member of Chinese Society of Clinical Oncology. Standing Committeemember of Chinese Oncologist Association. Committee member of IASLC TobaccoControl Committee. Executive Committee memebr of Chinese Society of ClinicalOncology Committee member of Shanghai Society of Pneumology and Shanghai Societyof Cancer.



主要致力于肺癌早期诊断、靶向治疗、免疫治疗、耐药机制等方面的研究。先后承担国家863、国家自然科学基金、上海市科委重大攻关等项目。在国内外刊物上发表论著200余篇，其中发表包括Lancet Oncology, JCO，Annals of Oncology, JTO，Cancer等在内SCI论文100余篇。并具有领导多中心临床研究经验，先后主持或参与30余项国内多中心肺癌临床研究。
Prof.Zhou mainly focuseson the research of early diagnosis, targeted therapy, immunotherapy, and drugresistance mechanisms of lung cancer. He has received research funds fromChinse government including national 863 project from the minister of Scienceand Technology, National Natural Science Foundation of China, key project fundsfrom the Science and Technology Commission of Shanghai Municipality. He haspublished more than 200 articles in domestic and foreign journals, includingmore than 100 SCI papers including Lancet Oncology, JCO, Annals of Oncology,JTO and Cancer. Prof.Zhou is experienced in leading multi-center clinicalresearch and he has initiated or participated in more than 30 clinical trialsin the field of lung cancer.